Open AccessA Genome-Wide Association Study of Nausea Incidence in Varenicline-Treated Cigarette Smokers
Author(s) -
Meghan J. Chenoweth,
Caryn Lerman,
Jo Knight,
Rachel F. Tyndale
Publication year - 2021
Publication title -
nicotine and tobacco research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.338
H-Index - 113
eISSN - 1469-994X
pISSN - 1462-2203
DOI - 10.1093/ntr/ntab044
Subject(s) - varenicline , medicine , nausea , incidence (geometry) , smoking cessation , cigarette smoking , pathology , physics , optics
Varenicline is the most efficacious smoking cessation treatment; however, long-term cessation rates tend to be <25%. Nausea, the most common side effect of varenicline, observed in ~28% of individuals treated, peaks early following treatment initiation and reduces cessation success. Genetic variation influences treatment response, however genetic contributors to individual differences in side effects are less understood.